1 week Ago By Defense World Staff
Knight Therapeutics Inc. ( TSE:GUD – Get Free Report )’s share price traded up 0.6% during trading on Friday .
The stock traded as high as C$5.41 and last traded at C$5.37.
22,259 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 37,893 shares. The stock had previously closed at C$5.34.
Analysts Set New Price Targets Separately, Raymond James raised shares of Knight Therapeutics to a “moderate buy” rating in a research note on Friday, November 15th. Get Our Latest Research Report on Knight Therapeutics Knight Therapeutics Stock Up 0.6 % Insider Activity at Knight Therapeutics In related news, Director Samira Sakhia purchased 20,000 shares of the firm’s stock in a transaction on Monday, November 11th.
The stock was purchased at an average price of C$5.15 per share, for a total transaction of C$103,000.00.
Also, insider Sime Armoyan acquired 90,300 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average price of C$5.13 per share, for a total transaction of C$463,672.
44. Company insiders own 45.62% of the company’s stock.
Knight Therapeutics Company Profile ( Get Free Report ) Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. Read More Five stocks we like better than Knight Therapeutics What is the Hang Seng index? Insiders Are Selling, But These 3 Stocks Are Must-Buys How to Calculate Retirement Income: MarketBeat’s Calculator Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge Industrial Products Stocks Investing Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’ Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
